REFERENCES
- Ishida J, Saitoh M, Ebner N, Springer J, D. Anker, Von Haehling.
Growth hormone secretagogues: history, mechanism of action, and
clinical development. JCSM Rapid Communications 2020; 3: 25–37. DOI:
10.1002/rco2.9.
- Bowers C, Chang J, Momany F, Folkers K. Effect of the enkephalins and
enkephalin analogs on release of pituitary hormones in vitro.Mol Endocrinol 1977;287–292.
- Bowers C, Momany F, Reynolds G: In vitro and in vivo activity
of a small synthetic pep- tide with potent GH releasing activity. In64th Annual Meeting of the Endocrine Soci- ety, San Francisco :
1982:205.
- Bowers C. GH releasing peptides-structure and kinetics. J
Paediatric Endocrinol Metabol 1993;6:21–32.
- Howard AD, Feighner SD, Cully DF, Arena JP. A receptor in pituitary
and hypothala- mus that functions in growth hormone re- lease.Science 1996;273:974.
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin
is a growth-hormone-releasing acylated pep- tide from stomach.Nature 1999;402: 656–660.
- Prakash A, Goa KL. Sermorelin. BioDrugs
- 1999;12:139–157.
- Barron JL, Coy DH, Millar RP. Growth hor- mone responses to growth
hormone- releasing hormine (1–29)-NH 2 and a D-Ala2
analog in normal men. Peptides 1985;6: 575–577.
- Carpino PA. Recent developments in ghrelin receptor (GHS-R1a) agonists
and antagonists. Expert Opin Ther Pat 2002; 12:1599–1618.
- Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, et
al. Effects of GHRP-2 and hexarelin, two synthetic GH- releasing
peptides, on GH, prolactin, ACTH and cortisol levels in man.
Comparison with the effects of GHRH, TRH and hCRH. Pep- tides1997;18:885–891.
- Imbimbo B, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, et al.
Growth hormone-releasing activity of hexarelin in humans. Eur J
Clin Pharmacol 1994;46: 421–425.
- Rahim A, O’Neill PA, Shalet SM. Growth hor- mone status during
long-term hexarelin therapy. J Clin Endocrinol Metabol 1998;
83:1644–1649.
- Broglio F, Benso A, Gottero C, Muccioli G, Deghenghi R, Ghigo E, et
al. Endocrine activities of alexamorelin (Ala-His-D-2-
methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), a synthetic GH
secretagogue, in humans. Eur J Endocrinol 2000;143:419–425.
- Suckling K. Discontinued drugs in 2005: car- diovascular drugs.Expert Opin Investig Drugs 2006;15:1299–1308.
- Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, et
al. Pharmaco- logical characterisation of a new oral GH se-
cretagogue, NN703. Eur J Endocrinol 1999; 141:180–189.
- Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen
MS, et al. The pharmacokinetics, pharmacodynamics, safety and
tolerability of a single dose of NN703, a novel orally active growth
hormone secretagogue in healthy male volunteers. Growth Horm IGF
Res 2000;10:193–198.
- Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch
JF, et al. The pharmacokinetics, pharmacodynamics, safety and
tolerability following 7 days daily oral treatment with NN703 in
healthy male subjects. Growth Horm IGF Res 2001;11: 41–48.
- Svensson J, Monson J, Vetter T, Hansen TK, Savine R, Kann P, et al.
Oral administration of the growth hormone secretagogue NN703 in adult
patients with growth hor- mone deficiency. Clin Endocrinol (Oxf)2003;58:572–580.
- Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, et al.
General pharmacology of KP-102 (GHRP-2), a po- tent growth
hormone-releasing peptide. Arzneimittelforschung2004;54:868–880.
- Editorial A. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing
peptide 2, KP- 102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R
& D 2004;5:236–239.
- Ejskjaer N, Dimcevski G, Wo J, Hellström PM, Gormsen L, Sarosiek I, et
al. Safety and efficacy of ghrelin agonist TZP-101 in re- lieving
symptoms in patients with diabetic gastroparesis: a randomized,
placebo- controlled study. Neurogastroenterol Motil2010;22:1069.
- Losa M, Schopohl J, Müller O, Von Werder K. Stimulation of growth
hormone secre- tion with human growth hormone releas- ing factors (GRF
1–44, GRF 1–40, GRF 1– 29) in normal subjects. J Mol Med1984;62:1140–1143.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis
and treatment of children with idiopathic growth hormone deficiency.BioDrugs: Clinic Immunothera- peutics, Biopharmaceut Gene
Therapy 1999;12:139–157.
- Neyzi O, Yordam N, Oca G, Bundak R, Darendeliler F, Agikǧoz E, et al.
Growth re- sponse to growth hormone releasing hor- mone (1–29)-NH2
compared with growth hormone. Acta Paediatr 1993;82:16–21.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al.
Once daily subcuta- neous growth hormone-releasing hormone therapy
accelerates growth in growth hormone-deficient children during the first
year of therapy. Geref International Study Group. J Clin
Endocrinol Metabol 1996; 81:1189–1196.
- Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS.
Growth hor- mone releasing hormone improves the cognition of healthy
older adults. Neurobiol Aging 2006;27:318–323.
- Mericq Vn, Cassorla F, Salazar T, Avila A, Iñiguez Gn, Bowers CY, et
al. Effects of eight months treatment with graded doses of a growth
hormone (GH)-releasing peptide in GH-deficient children. J Clin
Endocrinol Metabol 1998;83:2355–2360.
- Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, et al.
Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation
of a novel oral stimula- tion test for the diagnosis of adult GH defi-
ciency. J Clin Endocrinol Metabol 2013;98: 2422–2429.
- Beck DE, Sweeney WB, McCarter MD, Group IS. Prospective, randomized,
con- trolled, proof-of-concept study of the Ghrelin mimetic ipamorelin
for the manage- ment of postoperative ileus in bowel resec- tion
patients. Int J Colorectal Dis 2014;29: 1527–1534.
- Mosińska P, Zatorski H, Storr M, Fichna J. Future treatment of
constipation- associated disorders: role of relamorelin and other
ghrelin receptor agonists. J Neurogastroenterol Motility2017;23:171.
- Shaw M, Pediconi C, McVey D, Mondou E, Quinn J, Chamblin B, et al.
Safety and efficacy of ulimorelin administered postop- eratively to
accelerate recovery of gastroin- testinal motility following partial
bowel resection: results of two randomized, placebo-controlled phase 3
trials. Diseases of the Colon & Rectum 2013;56:888–897.
- Popescu I, Fleshner PR, Pezzullo JC, Charlton PA, Kosutic G, Senagore
AJ. The ghrelin agonist TZP-101 for management of postoperative ileus
after partial colectomy: a randomized, dose-ranging,
placebo-controlled clinical trial. Diseases of the Colon &
Rectum 2010;53:126–134.
- Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, et al.
Relamorelin re- duces vomiting frequency and severity and accelerates
gastric emptying in adults with diabetic gastroparesis.Gastroenterology 2016;151:87, e86–96.
- Acosta A, Camilleri M, Kolar G, Iturrino J, Szarka LA, Boldingh A, et
al. Relamorelin re- lieves constipation and accelerates colonic
transit in a phase 2, placebo-controlled, randomized trial. Clin
Gastroenterol Hepatol 2015, 13;2312, e2311–2319.
- Acosta A, Camilleri M, Busciglio I, Boldingh A, Nelson AD, Burton D.
Short-term effects of relamorelin on descending colon motility in
chronic constipation: a randomized, con- trolled trial. Dig Dis
Sci 2016;61:852–860.
- Ejskjaer N, Wo J, Esfandyari T, Mazen Jamal M, Dimcevski G, Tarnow L,
et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a
ghrelin receptor agonist for diabetic gastroparesis.Neurogastroenterol Motil 2013;25:e140–e150.
- Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, et
al. MK-0677 (ibutamoren mesylate) for the treatment of patients
recovering from hip fracture: a multicenter, randomized,
placebo-controlled phase IIb study. Arch Gerontol Geriatr2011;53:183–189.
- Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier
B, Routy J-P, Cote P, Abribat T. A placebo-controlled, dose- ranging
study of a growth hormone releas- ing factor in HIV-infected patients
with ab- dominal fat accumulation. AIDS 2005;19: 1279–1287.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al.
Metabolic effects of a growth hormone-releasing factor in pa- tients
with HIV. N Engl J Med 2007;357: 2359–2370.
- Falutz J, Allas S, Mamputu J-C, Assaad H, Zoltowska M, Michaud SE, et
al. Long-term safety and effects of tesamorelin, a growth
hormone-releasing factor analogue, in HIV patients with abdominal fat
accumulation. AIDS 2008;22:1719–1728.
- Falutz J, Potvin D, Mamputu J-C, Assaad H, Zoltowska M, Michaud S-E,
et al. Ef- fects of tesamorelin, a growth hormone- releasing factor,
in HIV-infected patients with abdominal fat accumulation: a ran-
domized placebo-controlled trial with a safety extension. JAIDS2010;53:311–322.
- White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et
al. Effects of an oral growth hormone secretagogue in older adults.J Clin Endocrinol Metabol 2009;94:1198–1206.
- Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC.
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced
non-small-cell lung cancer (NSCLC) patients with cachexia. Ann
Oncol 2017;28:1949–1956.
- Carty
M, Bowie
AG. SARM: From immune regulator to cell executioner.
Biochem
Pharmacol. 2019 Mar;161:52-62. doi: 10.1016/j.bcp.2019.01.005. Epub
2019 Jan 8.
- Fujii
S, Kagechika
H. Androgen receptor modulators: a review of recent patents and
reports (2012-2018).
Expert Opin Ther
Pat. 2019 Jun;29(6):439-453. doi: 10.1080/13543776.2019.1618831. Epub
2019 May 19.
- Fragkaki
AG, Sakellariou
P, Kiousi
P, Kioukia-Fougia
N, Tsivou
M, Petrou
M, Angelis
Y. Human in vivo metabolism study of LGD-4033.
Drug Test
Anal. 2018 Nov;10(11-12):1635-1645. doi: 10.1002/dta.2512. Epub 2018
Nov 8.
- Clark
RV, Walker
AC, Andrews
S, Turnbull
P, Wald
JA, Magee
MH. Safety, pharmacokinetics and pharmacological effects of the
selective androgen receptor modulator, GSK2881078, in healthy men and
postmenopausal women.
Br J Clin
Pharmacol. 2017 Oct;83(10):2179-2194. doi: 10.1111/bcp.13316. Epub
2017 Jun 10.
- Neil
D, Clark
RV, Magee
M, Billiard
J, Chan
A, Xue
Z, Russell
A. GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass
in Healthy Older Men and Women.
J Clin Endocrinol
Metab. 2018 Sep 1;103(9):3215-3224. doi: 10.1210/jc.2017-02644.
- Carty
M, Kearney
J, Shanahan
KA, Hams
E, Sugisawa
R, Connolly
D, Doran
CG, Muñoz-Wolf
N, Gürtler
C, Fitzgerald
KA, Lavelle
EC, Fallon
PG, Bowie
AG. Cell Survival and Cytokine Release after Inflammasome Activation
Is Regulated by the Toll-IL-1R Protein SARM.
Immunity. 2019
Jun 18;50(6):1412-1424.e6. doi: 10.1016/j.immuni.2019.04.005. Epub
2019 May 7.
- Piper
T, Dib
J, Putz
M, Fusshöller
G, Pop
V, Lagojda
A, Kuehne
D, Geyer
H, Schänzer
W, Thevis
M4. Studies on the in vivo metabolism of
the SARM YK11: Identification and characterization of metabolites
potentially useful for doping controls.
Drug Test
Anal. 2018 Nov;10(11-12):1646-1656. doi: 10.1002/dta.2527. Epub 2018
Nov 18.
- Ahram
M, Mustafa
E, Abu
Hammad
S, Alhudhud
M, Bawadi
R, Tahtamouni
L, Khatib
F, Zihlif
M. The cellular and molecular effects of the androgen receptor
agonist, Cl-4AS-1, on breast cancer cells.
Endocr Res. 2018
Aug;43(3):203-214. doi: 10.1080/07435800.2018.1455105. Epub 2018 Mar
26.
- Miller
CP, Shomali
M, Lyttle
CR, O’Dea
LS, Herendeen
H, Gallacher
K, Paquin
D, Compton
DR, Sahoo
B, Kerrigan
SA, Burge
MS, Nickels
M, Green
JL, Katzenellenbogen
JA, Tchesnokov
A, Hattersley
G. Design, Synthesis, and Preclinical Characterization of the
Selective Androgen Receptor Modulator (SARM) RAD140.
ACS Med Chem
Lett. 2010 Dec 2;2(2):124-9. doi: 10.1021/ml1002508. eCollection 2011
Feb 10.
- Crawford
J, Prado
CM, Johnston
MA, Gralla
RJ, Taylor
RP, Hancock
ML, Dalton
JT. Study Design and Rationale for the Phase 3 Clinical Development
Program of Enobosarm, a Selective Androgen Receptor Modulator, for the
Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER
Trials). Curr
Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0.
- Krishnan
V, Patel
NJ, Mackrell
JG, Sweetana
SA, Bullock
H, Ma
YL, Waterhouse
TH, Yaden
BC, Henck
J, Zeng
QQ, Gavardinas
K, Jadhav
P, Saeed
A, Garcia-Losada
P, Robins
DA, Benson
CT. Development of a selective androgen receptor modulator for
transdermal use in hypogonadal patients.
Andrology. 2018
May;6(3):455-464. doi: 10.1111/andr.12479. Epub 2018 Mar 12.
- Coss
CC, Jones
A, Dalton
JT. Pharmacokinetic drug interactions of the selective androgen
receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin,
probenecid, celecoxib and rosuvastatin.
Invest New
Drugs. 2016 Aug;34(4):458-67. doi: 10.1007/s10637-016-0353-8. Epub
2016 Apr 22.
- Welch
RD, Guo
C, Sengupta
M, Carpenter
KJ, Stephens
NA, Arnett
SA, Meyers
MJ, Sparks
LM, Smith
SR, Zhang
J, Burris
TP, Flaveny
CA. Rev-Erb co-regulates muscle regeneration via tethered interaction
with the NF-Y cistrome.
Mol
Metab. 2017 May 19;6(7):703-714. doi: 10.1016/j.molmet.2017.05.001.
eCollection 2017 Jul.
- Gu
L, Shi
Y, Xu
W, Ji
Y. PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes
Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1
Cells by Regulating miR-206.
Oncol Res. 2019
Aug 8;27(8):923-933. doi: 10.3727/096504019X15518706875814. Epub 2019
Apr 8.